Literature DB >> 15784726

Loss of Runx1 perturbs adult hematopoiesis and is associated with a myeloproliferative phenotype.

Joseph D Growney1, Hirokazu Shigematsu, Zhe Li, Benjamin H Lee, Jennifer Adelsperger, Rebecca Rowan, David P Curley, Jeffery L Kutok, Koichi Akashi, Ifor R Williams, Nancy A Speck, D Gary Gilliland.   

Abstract

Homozygous loss of function of Runx1 (Runt-related transcription factor 1 gene) during murine development results in an embryonic lethal phenotype characterized by a complete lack of definitive hematopoiesis. In light of recent reports of disparate requirements for hematopoietic transcription factors during development as opposed to adult hematopoiesis, we used a conditional gene-targeting strategy to effect the loss of Runx1 function in adult mice. In contrast with the critical role of Runx1 during development, Runx1 was not essential for hematopoiesis in the adult hematopoietic compartment, though a number of significant hematopoietic abnormalities were observed. Runx1 excision had lineage-specific effects on B- and T-cell maturation and pronounced inhibition of common lymphocyte progenitor production. Runx1 excision also resulted in inefficient platelet production. Of note, Runx1-deficient mice developed a mild myeloproliferative phenotype characterized by an increase in peripheral blood neutrophils, an increase in myeloid progenitor populations, and extramedullary hematopoiesis composed of maturing myeloid and erythroid elements. These findings indicate that Runx1 deficiency has markedly different consequences during development compared with adult hematopoiesis, and they provide insight into the phenotypic manifestations of Runx1 deficiency in hematopoietic malignancies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15784726      PMCID: PMC1895175          DOI: 10.1182/blood-2004-08-3280

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  63 in total

1.  Differential requirements for Runx proteins in CD4 repression and epigenetic silencing during T lymphocyte development.

Authors:  Ichiro Taniuchi; Motomi Osato; Takeshi Egawa; Mary Jean Sunshine; Suk Chul Bae; Toshihisa Komori; Yoshiaki Ito; Dan R Littman
Journal:  Cell       Date:  2002-11-27       Impact factor: 41.582

2.  Haematopoietic stem cells retain long-term repopulating activity and multipotency in the absence of stem-cell leukaemia SCL/tal-1 gene.

Authors:  Hanna K A Mikkola; Jenny Klintman; Haidi Yang; Hanno Hock; Thorsten M Schlaeger; Yuko Fujiwara; Stuart H Orkin
Journal:  Nature       Date:  2003-01-19       Impact factor: 49.962

Review 3.  Upstream and downstream targets of RUNX proteins.

Authors:  Florian Otto; Michael Lübbert; Michael Stock
Journal:  J Cell Biochem       Date:  2003-05-01       Impact factor: 4.429

4.  Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia.

Authors:  W J Song; M G Sullivan; R D Legare; S Hutchings; X Tan; D Kufrin; J Ratajczak; I C Resende; C Haworth; R Hock; M Loh; C Felix; D C Roy; L Busque; D Kurnit; C Willman; A M Gewirtz; N A Speck; J H Bushweller; F P Li; K Gardiner; M Poncz; J M Maris; D G Gilliland
Journal:  Nat Genet       Date:  1999-10       Impact factor: 38.330

5.  Mutations of the AML1 gene in acute myeloid leukemia of FAB types M0 and M7.

Authors:  Stephen E Langabeer; Rosemary E Gale; Sara J Rollinson; Gareth J Morgan; David C Linch
Journal:  Genes Chromosomes Cancer       Date:  2002-05       Impact factor: 5.006

6.  Role of Cbfb in hematopoiesis and perturbations resulting from expression of the leukemogenic fusion gene Cbfb-MYH11.

Authors:  Mondira Kundu; Amy Chen; Stacie Anderson; Martha Kirby; LiPing Xu; Lucio H Castilla; David Bodine; Pu Paul Liu
Journal:  Blood       Date:  2002-10-01       Impact factor: 22.113

7.  Cbf beta is involved in maturation of all lineages of hematopoietic cells during embryogenesis except erythroid.

Authors:  Mondira Kundu; P Paul Liu
Journal:  Blood Cells Mol Dis       Date:  2003 Mar-Apr       Impact factor: 3.039

8.  RUNX1 and GATA-1 coexpression and cooperation in megakaryocytic differentiation.

Authors:  Kamaleldin E Elagib; Frederick K Racke; Michael Mogass; Rina Khetawat; Lorrie L Delehanty; Adam N Goldfarb
Journal:  Blood       Date:  2003-02-06       Impact factor: 22.113

9.  The critical regulator of embryonic hematopoiesis, SCL, is vital in the adult for megakaryopoiesis, erythropoiesis, and lineage choice in CFU-S12.

Authors:  Mark A Hall; David J Curtis; Donald Metcalf; Andrew G Elefanty; K Sourris; Lorraine Robb; Joachim R Gothert; Stephen M Jane; C Glenn Begley
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-27       Impact factor: 11.205

10.  M0 AML, clinical and biologic features of the disease, including AML1 gene mutations: a report of 59 cases by the Groupe Français d'Hématologie Cellulaire (GFHC) and the Groupe Français de Cytogénétique Hématologique (GFCH).

Authors:  Christophe Roumier; Virginie Eclache; Michelle Imbert; Frederic Davi; Elizabeth MacIntyre; Richard Garand; Pascaline Talmant; Pascale Lepelley; Jean Luc Lai; Olivier Casasnovas; Marc Maynadie; Francine Mugneret; Chrystele Bilhou-Naberra; Francoise Valensi; Isabelle Radford; Marie Joelle Mozziconacci; Christine Arnoulet; Eliane Duchayne; Nicole Dastugue; Pascale Cornillet; Sylvie Daliphard; Francine Garnache; Najiba Boudjerra; Helene Jouault; Odile Fenneteau; Béatrice Pedron; Roland Berger; Georges Flandrin; Pierre Fenaux; Claude Preudhomme
Journal:  Blood       Date:  2002-10-10       Impact factor: 22.113

View more
  203 in total

1.  Opposing effects of Runx2 and estradiol on breast cancer cell proliferation: in vitro identification of reciprocally regulated gene signature related to clinical letrozole responsiveness.

Authors:  Nyam-Osor Chimge; Sanjeev K Baniwal; Jingqin Luo; Simon Coetzee; Omar Khalid; Benjamin P Berman; Debu Tripathy; Matthew J Ellis; Baruch Frenkel
Journal:  Clin Cancer Res       Date:  2011-12-06       Impact factor: 12.531

Review 2.  Factors and networks that underpin early hematopoiesis.

Authors:  Elinore M Mercer; Yin C Lin; Cornelis Murre
Journal:  Semin Immunol       Date:  2011-09-18       Impact factor: 11.130

Review 3.  Molecular biology of myelodysplastic syndromes.

Authors:  Alan H Shih; Ross L Levine
Journal:  Semin Oncol       Date:  2011-10       Impact factor: 4.929

4.  Tlx3 and Runx1 act in combination to coordinate the development of a cohort of nociceptors, thermoceptors, and pruriceptors.

Authors:  Claudia Lopes; Zijing Liu; Yi Xu; Qiufu Ma
Journal:  J Neurosci       Date:  2012-07-11       Impact factor: 6.167

5.  A Src family kinase-Shp2 axis controls RUNX1 activity in megakaryocyte and T-lymphocyte differentiation.

Authors:  Hui Huang; Andrew J Woo; Zachary Waldon; Yocheved Schindler; Tyler B Moran; Helen H Zhu; Gen-Sheng Feng; Hanno Steen; Alan B Cantor
Journal:  Genes Dev       Date:  2012-07-03       Impact factor: 11.361

Review 6.  C/EBPα deregulation as a paradigm for leukemogenesis.

Authors:  J A Pulikkan; D G Tenen; G Behre
Journal:  Leukemia       Date:  2017-07-19       Impact factor: 11.528

7.  Defining a tissue stem cell-driven Runx1/Stat3 signalling axis in epithelial cancer.

Authors:  Cornelia Johanna Franziska Scheitz; Tae Seung Lee; David James McDermitt; Tudorita Tumbar
Journal:  EMBO J       Date:  2012-10-02       Impact factor: 11.598

Review 8.  Cell cycle and developmental control of hematopoiesis by Runx1.

Authors:  Alan D Friedman
Journal:  J Cell Physiol       Date:  2009-06       Impact factor: 6.384

9.  Runx1 exon 6-related alternative splicing isoforms differentially regulate hematopoiesis in mice.

Authors:  Yukiko Komeno; Ming Yan; Shinobu Matsuura; Kentson Lam; Miao-Chia Lo; Yi-Jou Huang; Daniel G Tenen; James R Downing; Dong-Er Zhang
Journal:  Blood       Date:  2014-04-25       Impact factor: 22.113

10.  Runx1 controls terminal morphology and mechanosensitivity of VGLUT3-expressing C-mechanoreceptors.

Authors:  Shan Lou; Bo Duan; Linh Vong; Bradford B Lowell; Qiufu Ma
Journal:  J Neurosci       Date:  2013-01-16       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.